Millendo Therapeutics, Inc.
United States
72 articles about Millendo Therapeutics, Inc.
-
Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia
3/14/2019
Livoletide, a potential first-in-class treatment for Prader-Willi syndrome (PWS), will be featured in two poster sessions.
-
Millendo Therapeutics, Inc. to Present at the Cowen and Company 39th Annual Healthcare Conference and the Oppenheimer 29th Annual Healthcare Conference
3/4/2019
Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at two upcoming healthcare investor conferences.
-
Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2/21/2019
Millendo Therapeutics, Inc. announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 11:30 a.m. EST.
-
Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on January 28, 2019
2/1/2019
Millendo Therapeutics, Inc. announced that on January 28, 2019, the Compensation Committee of the Board of Directors approved, effective as of January 31, 2019, the grant of inducement stock options to purchase a total of 34,100 shares of the Company’s common stock to three newly-appointed employees of the Company.
-
Millendo Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/17/2019
The option awards have an exercise price of $8.80 per share, the closing price per share of the Company’s common stock on January 15, 2019.
-
Millendo Therapeutics Announces Successful Merger Completion with OvaScience, Inc
12/7/2018
Merger with OvaScience Closed
-
Shareholders raise concern over the fairness of the reverse merger and question potential conflicts of interest of OvaScience's co-founder.
-
Millendo Therapeutics Strengthens Executive Team with Key Appointments
11/14/2018
Millendo Therapeutics, Inc., a clinical-stage biotechnology company developing novel therapies for orphan endocrine diseases, today announced the appointments of Louis Arcudi III as Chief Financial Officer and Michael Yeh M.D., M.P.H., MBA as Vice President of Medical Affairs.
-
OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
11/1/2018
– New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million –
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
Millendo Therapeutics Appoints Habib Dable to Its Board of Directors
9/25/2018
Millendo Therapeutics, Inc., announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the Company’s Board of Directors.
-
Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of Nevanimibe in Patients with Classic Congenital Adrenal Hyperplasia
9/13/2018
Evaluates the efficacy and safety of its novel drug candidate, nevanimibe, in patients with classic congenital adrenal hyperplasia.
-
Millendo Therapeutics to Participate in Upcoming August 2018 Investor Conferences
8/10/2018
Millendo Therapeutics, Inc. announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will participate in the following August conferences:
-
OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
8/9/2018
Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome
-
Beleaguered OvaScience is Absorbed in Reverse Merger by Michigan-based Millendo Therapeutics
8/9/2018
Shares of struggling OvaScience have dipped 8 percent this morning after the company announced it entered into an all-stock reverse merger agreement with privately-held Millendo Therapeutics, Inc. of Ann Arbor, Mich. -
Millendo Therapeutics Appoints Dr. Ryan Zeidan as Senior Vice President, Development and Strengthens Leadership Team with Key Promotions
6/28/2018
Millendo Therapeutics, Inc. today announced the appointment of Ryan Zeidan, Ph.D., as Senior Vice President, Development.
-
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
-
Millendo Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference
3/15/2018
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 28th Annual Healthcare Conference on Wednesday, March 21, 2018 at 3:55 PM ET in New York, NY.
-
Millendo Therapeutics announced that it has acquired Alize Pharma SAS in a stock-based transaction.
-
Millendo Therapeutics Announces Positive Topline Phase II Results of ATR-101 in Classic Congenital Adrenal Hyperplasia
11/8/2017
ATR-101 was well-tolerated at all dose levels.